昭衍新药

- 603127

-

-  -

-
昨收盘:- 今开盘:- 最高价:- 最低价:-
市值:-亿元 流通:- 成交:-手 换手:-
历年数据:  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014 
昭衍新药(603127) 利润表
单位:万元
报表日期2024-06-302024-03-312023-12-312023-09-302023-06-30
一、营业总收入84,935.6532,480.91237,648.68158,707.98101,207.73
营业收入84,935.6532,480.91237,648.68158,707.98101,207.73
二、营业总成本75,306.2529,329.46162,201.02110,483.7271,419.66
营业成本59,142.3421,815.70136,370.1189,245.5656,350.97
营业税金及附加538.46236.97767.61574.08330.04
销售费用1,216.31585.052,461.511,833.261,186.61
管理费用15,635.077,196.1728,025.4822,923.6815,249.29
财务费用-6,009.90-2,801.15-15,109.12-11,856.83-7,390.60
研发费用4,783.972,296.739,685.447,763.975,693.34
资产减值损失----------
公允价值变动收益-25,719.02-31,001.29-24,564.15-10,851.39-19,767.09
投资收益2,801.92697.20962.78714.17584.35
其中:对联营企业和合营企业的投资收益1,547.13-55.87-306.92-255.31-167.90
汇兑收益----------
三、营业利润-17,715.47-29,300.8350,709.6339,208.4911,683.91
加:营业外收入10.911.0438.6723.5922.19
减:营业外支出30.5413.2153.2633.5712.54
其中:非流动资产处置损失----------
四、利润总额-17,735.11-29,313.0050,695.0439,198.5211,693.57
减:所得税费用-511.28-1,976.6411,539.796,578.822,742.75
五、净利润-17,223.83-27,336.3639,155.2632,619.708,950.82
归属于母公司所有者的净利润-16,974.26-27,222.2539,699.2632,759.849,062.72
少数股东损益-249.57-114.11-544.00-140.14-111.90
六、每股收益
基本每股收益(元/股)-0.2300-0.36000.53000.44000.1700
稀释每股收益(元/股)-0.2300-0.36000.53000.44000.1700
七、其他综合收益302.4986.38496.081,018.421,325.21
八、综合收益总额-16,921.34-27,249.9839,651.3333,638.1210,276.03
归属于母公司所有者的综合收益总额-16,671.77-27,135.8740,195.3333,778.2610,387.93
归属于少数股东的综合收益总额-249.57-114.11-544.00-140.14-111.90
下载全部历史数据到excel中 返回页顶